Andrew Baum
Stock Analyst at Citigroup
(2.88)
# 1,545
Out of 5,152 analysts
67
Total ratings
76.74%
Success rate
15%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $53 → $60 | $60.74 | -1.22% | 15 | Jan 27, 2026 | |
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $26.61 | -2.29% | 11 | Aug 6, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $116.07 | -0.92% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $45.68 | -12.43% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $232.35 | -7.47% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $983.26 | -8.98% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $4.16 | +140.38% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $55.27 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Jan 27, 2026
Maintains: Neutral
Price Target: $53 → $60
Current: $60.74
Upside: -1.22%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $26.61
Upside: -2.29%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $116.07
Upside: -0.92%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $45.68
Upside: -12.43%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $232.35
Upside: -7.47%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $983.26
Upside: -8.98%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $4.16
Upside: +140.38%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $55.27
Upside: -